EMA Authorised: Hemlibra (emicizumab) — Roche Registration Limited

View source ↗

Summary

The EMA authorised Hemlibra (emicizumab) for Hemophilia A with Roche Registration Limited as the marketing authorization holder, decision dated 27 March 2025 (a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Hemlibra (emicizumab)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A. MAH: Roche Registration Limited. Decision date: 27/03/2025. Accelerated assessment